MA45470A - Acides nucléiques kras et leurs utilisations - Google Patents
Acides nucléiques kras et leurs utilisationsInfo
- Publication number
- MA45470A MA45470A MA045470A MA45470A MA45470A MA 45470 A MA45470 A MA 45470A MA 045470 A MA045470 A MA 045470A MA 45470 A MA45470 A MA 45470A MA 45470 A MA45470 A MA 45470A
- Authority
- MA
- Morocco
- Prior art keywords
- nucleic acids
- kras nucleic
- kras
- acids
- nucleic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316937P | 2016-04-01 | 2016-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45470A true MA45470A (fr) | 2019-02-06 |
Family
ID=59960270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045470A MA45470A (fr) | 2016-04-01 | 2017-03-31 | Acides nucléiques kras et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10858656B2 (fr) |
| EP (1) | EP3436585B1 (fr) |
| MA (1) | MA45470A (fr) |
| WO (1) | WO2017173304A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| EP3436585B1 (fr) | 2016-04-01 | 2022-07-20 | Avidity Biosciences, Inc. | Acides nucléiques kras et leurs utilisations |
| EP3691657A4 (fr) | 2017-10-04 | 2021-07-21 | Avidity Biosciences, Inc. | Compositions d'acide nucléique-polypeptide et utilisations de celles-ci |
| EP3735252A4 (fr) * | 2018-01-04 | 2021-10-06 | Avidity Biosciences, Inc. | Molécules d'acide nucléique hétéroduplex et leurs utilisations |
| BR112021018739A2 (pt) * | 2019-03-29 | 2022-05-03 | Dicerna Pharmaceuticals Inc | Composições e métodos para o tratamento de doenças ou distúrbios associados a kras |
| CN114375296A (zh) | 2019-06-06 | 2022-04-19 | 艾维迪提生物科学公司 | 核酸多肽组合物及其用途 |
| US12006499B2 (en) | 2019-06-06 | 2024-06-11 | Avidity Biosciences, Inc. | Una amidites and uses thereof |
| JP7839554B2 (ja) * | 2020-04-07 | 2026-04-02 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986005519A1 (fr) | 1985-03-15 | 1986-09-25 | James Summerton | Reactif et procede d'analyse de polynucleotides |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| ES2061416T3 (es) | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5610052A (en) | 1992-08-26 | 1997-03-11 | Ribozyme Pharmaceuticals Inc. | Enzymatic RNA with activity to ras |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| WO1997026270A2 (fr) | 1996-01-16 | 1997-07-24 | Ribozyme Pharmaceuticals, Inc. | Synthese de methoxy nucleosides et de molecules d'acide nucleique enzymatique |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| EP1071753A2 (fr) | 1998-04-20 | 2001-01-31 | Ribozyme Pharmaceuticals, Inc. | Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| CA2328356A1 (fr) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Vehicules recreatifs |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| EP2796553B1 (fr) | 2000-03-30 | 2019-06-19 | Whitehead Institute for Biomedical Research | Médiateurs spécifiques de la séquence d'ARN d'interférence d'ARN |
| CA2429814C (fr) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Petites molecules d'arn mediant l'interference arn |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| EP1386004A4 (fr) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique |
| DE10133858A1 (de) | 2001-07-12 | 2003-02-06 | Aventis Pharma Gmbh | Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression |
| US20040121348A1 (en) | 2001-10-26 | 2004-06-24 | Ribopharma Ag | Compositions and methods for treating pancreatic cancer |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| EP1432724A4 (fr) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | Inhibition a mediation par interference d'arn de genes de map kinase |
| US20040023220A1 (en) | 2002-07-23 | 2004-02-05 | Lawrence Greenfield | Integrated method for PCR cleanup and oligonucleotide removal |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003291755A1 (en) * | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| EP1633890B2 (fr) | 2003-06-02 | 2020-11-18 | University of Massachusetts | Methodes et compostions permettant d'ameliorer l'efficacite et la specificite d'une interference d'arn |
| PT1633767T (pt) | 2003-06-02 | 2019-02-27 | Univ Massachusetts | Métodos e composições para controlar a eficácia do silenciamento de arn |
| AU2004263830B2 (en) | 2003-06-13 | 2008-12-18 | Alnylam Pharmaceuticals, Inc. | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| CA2559955C (fr) | 2004-03-15 | 2016-02-16 | City Of Hope | Procedes et compositions pour l'inhibition specifique de l'expression genetique par l'arn double brin |
| AU2005247509C1 (en) | 2004-05-27 | 2012-09-20 | Alnylam Pharmaceuticals, Inc. | Nuclease resistant double-stranded ribonucleic acid |
| EP2121925A2 (fr) | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Composes d'acide nucleique pour inhiber l'expression du gene ras et utilisations de ceux-ci |
| JP2010538678A (ja) | 2007-09-18 | 2010-12-16 | イントラドイグム コーポレーション | Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法 |
| EP2195428B1 (fr) | 2007-09-19 | 2013-12-11 | Applied Biosystems, LLC | Formats de modification indépendants d'une séquence d'arnsi pour réduire des effets phénotypiques hors cible dans de l'arni, et formes stabilisées de ceux-ci |
| WO2009099942A2 (fr) | 2008-01-31 | 2009-08-13 | Alnylam Pharmaceuticals, Inc. | Oligonucléotides modifiés chimiquement et leurs utilisations |
| CA2715289C (fr) | 2008-02-11 | 2019-12-24 | Rxi Pharmaceuticals Corporation | Polynucleotides d'arni modifies et leurs utilisations |
| WO2010028054A1 (fr) | 2008-09-02 | 2010-03-11 | Alnylam Europe Ag. | Compositions et procédés d'inhibition de l'expression d'un gène egfr mutant |
| EP2342340A1 (fr) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Emploi d'arni dans des applications dermatologiques |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| CN103555722B (zh) | 2009-04-03 | 2016-08-31 | 戴瑟纳制药公司 | 利用不对称双链rna特异性抑制kras的方法和组合物 |
| CN102459298A (zh) | 2009-05-05 | 2012-05-16 | 阿尔特姆恩科技责任有限公司 | 化学可编程免疫 |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| SI3366775T2 (sl) | 2011-11-18 | 2025-12-31 | Alnylam Pharmaceuticals, Inc. | Modificirana sredstva RNAI |
| US20150299696A1 (en) * | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| EA201492004A1 (ru) * | 2012-05-02 | 2015-08-31 | Новартис Аг | Органические композиции для лечения kras-ассоциированных заболеваний |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| DK2978845T3 (da) | 2013-03-27 | 2020-08-10 | Isarna Therapeutics Gmbh | Modificerede tgf-beta-oligonukleotider |
| WO2014169049A1 (fr) | 2013-04-09 | 2014-10-16 | Duke University | Arn 2'fluoro-modifiés en tant qu'immunostimulateurs |
| US10266828B2 (en) | 2013-12-16 | 2019-04-23 | Syddansk Universitet | RAS exon 2 skipping for cancer treatment |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| US10988764B2 (en) | 2014-06-23 | 2021-04-27 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| EP3436585B1 (fr) | 2016-04-01 | 2022-07-20 | Avidity Biosciences, Inc. | Acides nucléiques kras et leurs utilisations |
-
2017
- 2017-03-31 EP EP17776795.1A patent/EP3436585B1/fr active Active
- 2017-03-31 MA MA045470A patent/MA45470A/fr unknown
- 2017-03-31 US US15/476,102 patent/US10858656B2/en active Active
- 2017-03-31 WO PCT/US2017/025434 patent/WO2017173304A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3436585A4 (fr) | 2019-11-13 |
| US20170283806A1 (en) | 2017-10-05 |
| EP3436585B1 (fr) | 2022-07-20 |
| WO2017173304A1 (fr) | 2017-10-05 |
| US10858656B2 (en) | 2020-12-08 |
| EP3436585A1 (fr) | 2019-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1023I2 (fr) | Anticorps thérapeutiques et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| EP3426288A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3352776A4 (fr) | Répresseurs htt et leurs utilisations | |
| EP3377102C0 (fr) | Anticorps anti-pd-1 et leurs utilisations thérapeutiques | |
| EP3481430A4 (fr) | Conjugués de type acide nucléique et leurs utilisations | |
| EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| MA45470A (fr) | Acides nucléiques kras et leurs utilisations | |
| EP3383904A4 (fr) | Anticorps ctla-4 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| EP3538261A4 (fr) | Catalyseurs en pérovskite et leurs utilisations | |
| EP3341007A4 (fr) | Inhibiteurs de malt1 et leurs utilisations | |
| EP3347021A4 (fr) | Cyano-thiénotriazoloazépines et leurs utilisations | |
| EP3347020A4 (fr) | Acétamide thiénotriazoldiazépines et leurs utilisations | |
| MA46945A (fr) | Exopolysaccharides et leurs utilisations | |
| EP3370771A4 (fr) | Conjugués anti-cd3-folate et leurs utilisations | |
| MA46562A (fr) | Anticorps anti-chikv et leurs utilisations | |
| EP3526186A4 (fr) | Hydroxystilbènes substitués et leurs applications thérapeutiques | |
| EP3445768A4 (fr) | Inhibiteurs de erbb et leurs utilisations | |
| MA44789A (fr) | Inhibiteurs covalents de btk et leurs utilisations |